Fig. 5.
Pharmacokinetics of chimeric activator 10F7-EPOR150A. (A) Compartment model of the expected biodistribution and elimination of 10F7-EPOR150A. Drug enters the plasma, where it immediately binds mature huGYPA-expressing RBCs (red box) that act as a drug sink. Free drug in the plasma can enter other tissues to stimulate expansion of late RBC precursors (red box) or other EPO-R–positive cell types. (B) huGYPA transgenic or nontransgenic mice were given a single i.v. 100-μg dose of 10F7-EPOR150A. (C and D) Blood was collected in a time course to measure drug in plasma by ELISA (C) or RBC-bound drug by flow cytometry (D). Measurements are relative to amount of drug detected at T = 0 (100%). Graphs display mean ± SEM (n = 2) and the terminal plasma and RBC-bound half-lives of 10F7-EPOR150A in huGYPA transgenic and nontransgenic mice.